- Report
- September 2023
- 180 Pages
Global
From €5717EUR$5,950USD£4,908GBP
- Report
- January 2024
- 190 Pages
Global
From €4708EUR$4,900USD£4,042GBP
- Report
- January 2024
- 87 Pages
Global
From €3795EUR$3,950USD£3,258GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1201EUR$1,250USD£1,031GBP
- Drug Pipelines
- January 2019
- 60 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Report
- January 2022
- 60 Pages
Global
From €3795EUR$3,950USD£3,258GBP
- Report
- January 2022
- 60 Pages
Global
From €3795EUR$3,950USD£3,258GBP
- Report
- July 2022
- 155 Pages
Global
From €7206EUR$7,500USD£6,186GBP
- Report
- January 2022
- 200 Pages
Global
From €7206EUR$7,500USD£6,186GBP
- Report
- August 2022
Global
From €759EUR$790USD£652GBP
- Drug Pipelines
- June 2020
- 93 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Clinical Trials
- October 2021
- 121 Pages
Global
From €2402EUR$2,500USD£2,062GBP
- Report
- March 2021
- 49 Pages
Global
From €3358EUR$3,495USD£2,883GBP
- Clinical Trials
- October 2020
- 111 Pages
Global
From €2402EUR$2,500USD£2,062GBP
- Clinical Trials
- October 2020
- 118 Pages
Global
From €2402EUR$2,500USD£2,062GBP
- Clinical Trials
- July 2020
- 247 Pages
Global
From €2402EUR$2,500USD£2,062GBP
- Report
- May 2023
- 85 Pages
Global
From €3500EUR$3,902USD£3,110GBP
- Report
- November 2022
- 92 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Report
- April 2021
- 30 Pages
Global
From €1922EUR$2,000USD£1,650GBP
The Retinal Vein Occlusion Drug market is a subset of the Optical Disorders Drugs market, which includes drugs used to treat a variety of eye conditions. Retinal Vein Occlusion (RVO) is a condition in which the veins in the retina become blocked, leading to vision loss. RVO drugs are used to reduce the risk of vision loss and improve vision in patients with RVO. These drugs include anti-VEGF agents, corticosteroids, and other medications.
RVO drugs are used to reduce the risk of vision loss and improve vision in patients with RVO. These drugs are typically administered via intravitreal injections, which are injections directly into the eye.
The Retinal Vein Occlusion Drug market is highly competitive, with many companies offering a variety of drugs to treat RVO. Some of the major players in the market include Regeneron Pharmaceuticals, Allergan, Novartis, Bayer, and Roche. Show Less Read more